Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

Original Submission
18 Jun 2017 Submitted Original manuscript
19 Jul 2017 Reviewed Reviewer Report - Alessandro Sindoni
6 Aug 2017 Reviewed Reviewer Report - Giovanni Grignani
27 Aug 2017 Author responded Author comments - Andrea Ungari
Resubmission - Version 2
27 Aug 2017 Submitted Manuscript version 2
31 Aug 2017 Reviewed Reviewer Report - Alessandro Sindoni
1 Sep 2017 Reviewed Reviewer Report - Giovanni Grignani
15 Sep 2017 Author responded Author comments - Andrea Ungari
Resubmission - Version 3
15 Sep 2017 Submitted Manuscript version 3
Publishing
9 Oct 2017 Editorially accepted
17 Oct 2017 Article published 10.1186/s12885-017-3679-5

You can find further information about peer review here.

Back to article page